artelo
biosciences
inc
announces
pricing
million
upsized
underwritten
public
offering
la
jolla
globe
newswire
artelo
biosciences
nasdaq
artl
clinical
stage
biopharmaceutical
company
focused
developing
commercializing
treatments
intended
modulate
endogenous
signaling
pathways
including
endocannabinoid
system
today
announced
pricing
underwritten
public
offering
units
gross
proceeds
approximately
million
prior
deducting
underwriting
discounts
commissions
offering
expenses
payable
artelo
biosciences
inc
offering
comprised
million
units
priced
public
offering
price
per
unit
unit
consisting
one
share
common
stock
warrant
purchase
one
share
common
stock
exercise
price
per
share
expires
fifth
anniversary
date
issuance
securities
comprising
units
immediately
separable
issued
separately
closing
offering
expected
take
place
october
subject
satisfaction
waiver
customary
closing
conditions
ladenburg
thalmann
acting
sole
manager
total
shares
common
stock
warrants
purchase
shares
common
stock
issued
offering
addition
company
granted
underwriters
option
purchase
additional
shares
common
stock
additional
warrants
purchase
shares
common
stock
solely
cover
public
offering
price
per
unit
less
underwriting
discounts
commissions
securities
offered
pursuant
registration
statement
form
file
declared
effective
united
states
securities
exchange
commission
sec
october
press
release
constitute
offer
sell
solicitation
offer
buy
sales
securities
jurisdiction
offer
solicitation
sale
would
unlawful
prior
registration
qualification
securities
laws
jurisdiction
offering
made
solely
means
prospectus
preliminary
prospectus
relating
proposed
offering
filed
sec
october
available
sec
website
located
http
final
prospectus
relating
offering
filed
artelo
biosciences
sec
available
copies
final
prospectus
obtained
sec
website
ladenburg
thalmann
prospectus
department
park
avenue
floor
new
york
new
york
email
prospectus
statements
press
release
contains
statements
within
meaning
private
securities
litigation
reform
act
statements
include
statements
regarding
artelo
expectations
respect
completion
timing
size
public
offering
expected
gross
proceeds
public
offering
anticipated
use
net
proceeds
proposed
offering
risks
uncertainties
related
endeavors
include
limited
risks
uncertainties
associated
market
conditions
satisfaction
customary
closing
conditions
related
public
offering
statements
based
management
current
expectations
subject
various
risks
uncertainties
could
cause
actual
results
differ
materially
adversely
expressed
implied
statements
accordingly
statements
constitute
guarantees
future
performance
cautioned
place
undue
reliance
statements
risks
regarding
artelo
business
described
detail
sec
filings
statements
speak
date
hereof
disclaim
obligation
update
statements
except
may
required
law
investor
relations
contact
crescendo
communications
llc
tel
email
artl
